BSTC News and Press, BioSpecifics Technologies Corp From 07/20/20

WILMINGTON, Del. , July 20, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) (the "Company"), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX ® in ...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Our analysis concludes that if the sNDA filed by BioSpecifics Technologies' (BSTC) commercial partner, Endo International PLC (ENDP), for the use of BSTC's injectable collagenase ("CCH") in a product called XiaFlex to treat cellulite of the buttocks, is approved by the FDA as anticipated on Ju...

BioSpecifics Tech (NASDAQ: BSTC ): Q1 GAAP EPS of $0.61 misses by $0.15 . More news on: BioSpecifics Technologies Corp., Earnings news and commentary, Healthcare stocks news, Read more ...

WILIMINGTON, Del., May 11, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX ®  in North A...

WILIMINGTON, Del., May 11, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX ® in North America , t...

WILMINGTON, Del. , April 10, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in North Am...

BioSpecifics Technologies (NASDAQ: BSTC ) has appointed Joseph Truitt as interim Chief Executive Officer (CEO). He will also serve on the Company's Board of Directors. More news on: BioSpecifics Technologies Corp., Healthcare stocks news, Read more ...

WILIMINGTON, Del., April 9, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX ®  in North Ameri...

WILIMINGTON, Del., April 9, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX® in North America...